Results 171 to 180 of about 6,357 (207)

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Lancet, The, 2007
Alain Ravaud, Sergio Bracarda, C?zary A Szczylik   +2 more
exaly  

Epoetin Alfa

2017
openaire   +1 more source

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Lancet, The, 2005
Harry La Janssen, Yilmaz Cakaloglu, Guido Gerken   +2 more
exaly  

Betamethasone/epoetin-alfa

Reactions Weekly, 2023
openaire   +1 more source

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Journal of Clinical Oncology, 2008
Brian I Rini, Susan Halabi
exaly  

Ciclosporin/epoetin-alfa

Reactions Weekly, 2023
openaire   +1 more source

The ALFA-tag is a highly versatile tool for nanobody-based bioscience applications

Nature Communications, 2019
Hansjörg Götzke, Markel Martínez-Carranza, Shama Sograte-Idrissi   +2 more
exaly  

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2014
Michael Manns, Maria Buti, Ewa Janczewska   +2 more
exaly  

Epoetin Alfa

2020
openaire   +1 more source

Epoetin-alfa/stanozolol

Reactions Weekly, 2021
openaire   +1 more source